ATE229943T1 - Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen - Google Patents

Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen

Info

Publication number
ATE229943T1
ATE229943T1 AT98105754T AT98105754T ATE229943T1 AT E229943 T1 ATE229943 T1 AT E229943T1 AT 98105754 T AT98105754 T AT 98105754T AT 98105754 T AT98105754 T AT 98105754T AT E229943 T1 ATE229943 T1 AT E229943T1
Authority
AT
Austria
Prior art keywords
substituted
imidazo
amines
quinoline
production
Prior art date
Application number
AT98105754T
Other languages
English (en)
Inventor
John F Gerster
Stephen L Crooks
Kyle J Lindstrom
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Application granted granted Critical
Publication of ATE229943T1 publication Critical patent/ATE229943T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
AT98105754T 1991-03-01 1992-02-20 Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen ATE229943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66292691A 1991-03-01 1991-03-01
US68732691A 1991-04-18 1991-04-18

Publications (1)

Publication Number Publication Date
ATE229943T1 true ATE229943T1 (de) 2003-01-15

Family

ID=27098631

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98105754T ATE229943T1 (de) 1991-03-01 1992-02-20 Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen
AT92906763T ATE179711T1 (de) 1991-03-01 1992-02-20 1,2-substituierte 1h-imidazo(4,5-c>chinolin-4- amine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT92906763T ATE179711T1 (de) 1991-03-01 1992-02-20 1,2-substituierte 1h-imidazo(4,5-c>chinolin-4- amine

Country Status (18)

Country Link
EP (2) EP0872478B1 (de)
JP (1) JP2955019B2 (de)
AT (2) ATE229943T1 (de)
AU (2) AU658621B2 (de)
CA (2) CA2104782C (de)
CZ (1) CZ285050B6 (de)
DE (2) DE69232878T2 (de)
DK (2) DK0582581T3 (de)
ES (2) ES2131070T3 (de)
HU (5) HU222250B1 (de)
IE (1) IE920605A1 (de)
IL (2) IL114570A (de)
NO (1) NO303729B1 (de)
NZ (1) NZ241784A (de)
PH (1) PH31614A (de)
SG (2) SG46492A1 (de)
UA (1) UA32546C2 (de)
WO (1) WO1992015582A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
DE69425661T2 (de) * 1993-07-15 2001-04-19 Minnesota Mining & Mfg IMIDAZO [4,5-c]PYRIDIN-4-AMINE
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US6133547A (en) * 1996-09-05 2000-10-17 Medtronic, Inc. Distributed activator for a two-dimensional shape memory alloy
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JPH10298181A (ja) * 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
EP1541572A1 (de) * 2000-12-08 2005-06-15 3M Innovative Properties Company Thioether substituierte Imidazochinoline
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
DK1543002T3 (da) * 2002-07-23 2006-12-27 Teva Gyogyszergyar Zartkoeruee Fremstilling af 1H-imidazo (4,5-c) quinolin-4-aminer via 1H-imidazo (4,5-c) quinolin-4-phtalimid mellemprodukter
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
CA2571360C (en) * 2004-06-18 2014-11-25 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines useful in inducing cytokine biosynthesis in animals
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
NZ561042A (en) 2005-02-18 2011-03-31 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052
WO2006091567A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2598437A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
EP1851224A2 (de) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl-substituierte imidazochinoline
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
US10842867B2 (en) 2005-11-04 2020-11-24 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ567979A (en) 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
US8088790B2 (en) * 2005-11-04 2012-01-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
WO2007052058A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
BRPI0707300B8 (pt) 2006-01-27 2021-05-25 Novartis Ag vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica
AU2007231027B2 (en) 2006-03-24 2013-10-03 Novartis Influenza Vaccines Marburg Gmbh Storage of influenza vaccines without refrigeration
CA2647942A1 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
EP2035035A2 (de) 2006-06-09 2009-03-18 Novartis AG Immunogene zusammensetzungen für streptococcus agalactiae
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2659733A1 (en) 2006-07-31 2008-02-07 3M Innovative Properties Company Sterilized topical compositions of 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli
MX2009002408A (es) 2006-09-11 2009-03-20 Novartis Ag Elaboracion de vacunas para el virus de la influenza sin utilizar huevos.
EP2121011B1 (de) 2006-12-06 2014-05-21 Novartis AG Impfstoffe mit antigen aus vier stämmen des influenzavirus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2686163A1 (en) * 2007-05-08 2008-11-13 Astrazenca Ab Imidazoquinolines with immuno-modulating properties
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PL2268618T3 (pl) * 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
CA2718430A1 (en) 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
CA2719544C (en) * 2008-03-24 2018-01-09 4Sc Ag Substituted imidazoquinolines
JP2012519482A (ja) 2009-03-06 2012-08-30 ノバルティス アーゲー クラミジア抗原
DK2510947T3 (en) 2009-04-14 2016-03-21 Glaxosmithkline Biolog Sa Compositions for Immunization against Staphylococcus aureus.
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
EP2451833B1 (de) 2009-07-07 2018-01-17 GlaxoSmithKline Biologicals SA Konservierte escherichia-coli-immunogene
ES2563730T3 (es) 2009-07-15 2016-03-16 Glaxosmithkline Biologicals S.A. Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
DK2464658T3 (en) 2009-07-16 2014-12-15 Novartis Ag Detoxified escherichia coli immunogens
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011084725A1 (en) * 2009-12-21 2011-07-14 3M Innovative Properties Company 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
WO2011084726A1 (en) * 2009-12-21 2011-07-14 3M Innovative Properties Company BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
CA2798323A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9517205B2 (en) 2010-08-20 2016-12-13 Seqirus UK Limited Soluble needle arrays for delivery of influenza vaccines
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
DK2667892T3 (da) 2011-01-26 2019-05-13 Glaxosmithkline Biologicals Sa RSV-vaccineringsprogram
HUE034673T2 (en) 2011-05-13 2018-02-28 Glaxosmithkline Biologicals Sa Pre-fusion Rsv F antigens
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
EP2903650B1 (de) 2012-10-02 2018-04-04 GlaxoSmithKline Biologicals SA Nichtlineare saccharidkonjugate
ES2826555T3 (es) 2012-11-30 2021-05-18 Glaxosmithkline Biologicals Sa Antígenos de Pseudomonas y combinación de antígenos
JP6463276B2 (ja) * 2013-02-01 2019-01-30 ウェルスタット セラピューティクス コーポレイション 抗炎症、抗真菌、抗寄生生物及び抗癌活性を有するアミン化合物
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
BR112016022011A2 (pt) 2014-03-26 2017-10-24 Glaxosmithkline Biologicals Sa ?antígeno de proteína estafilocócica a mutante, proteína de fusão, e, composição imunogênica?
MX2016013689A (es) 2014-04-22 2017-01-20 Hoffmann La Roche Compuestos 4-amino-imidazoquinolina.
SI3265458T1 (sl) 2015-03-06 2019-03-29 F. Hoffmann-La Roche Ag Benzazepin dikarboksamidne spojine
EP3350178B1 (de) * 2015-09-14 2021-10-20 Pfizer Inc. Neuartige imidazo[4,5-c]chinolin- und imidazo[4,5-c][1,5]naphthyridin-derivate als lrrk2-inhibitoren
EP3350168B1 (de) 2015-09-17 2019-12-18 H. Hoffnabb-La Roche Ag Sulfinylphenyl oder sulfonimidoylphenyl benzazepine
JP6918838B2 (ja) 2016-05-23 2021-08-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物
EP3464274B1 (de) 2016-05-23 2020-05-27 H. Hoffnabb-La Roche Ag Benzazepindicarboxamidverbindungen mit sekundärer amidfunktion
WO2017216054A1 (en) 2016-06-12 2017-12-21 F. Hoffmann-La Roche Ag Dihydropyrimidinyl benzazepine carboxamide compounds
TWI674261B (zh) * 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
EP3625231B1 (de) * 2017-05-19 2022-07-20 Superb Wisdom Limited Derivate von resiquimod
JP7080501B2 (ja) * 2017-06-23 2022-06-06 バーディー バイオファーマシューティカルズ インコーポレイテッド 医薬品組成物
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
DK0385630T3 (da) * 1989-02-27 1997-05-12 Riker Laboratories Inc 1H-imidazo(4,5-c)quinolin-4-aminer som antivirale midler

Also Published As

Publication number Publication date
CA2104782C (en) 2001-08-07
AU658621B2 (en) 1995-04-27
JPH06504789A (ja) 1994-06-02
HU222251B1 (hu) 2003-05-28
NZ241784A (en) 1995-06-27
IL114570A0 (en) 1995-11-27
HUT67026A (en) 1995-01-30
CZ178893A3 (en) 1995-10-18
DK0872478T3 (da) 2003-03-31
HU9701089D0 (en) 1997-08-28
CA2289219C (en) 2003-05-20
ES2131070T3 (es) 1999-07-16
EP0582581B1 (de) 1999-05-06
CZ285050B6 (cs) 1999-05-12
IL101110A (en) 1995-12-08
HU211242A9 (en) 1995-11-28
CA2104782A1 (en) 1992-09-02
NO303729B1 (no) 1998-08-24
ATE179711T1 (de) 1999-05-15
IL114570A (en) 1996-10-31
DK0582581T3 (da) 1999-11-08
EP0872478A2 (de) 1998-10-21
ES2186034T3 (es) 2003-05-01
DE69229114T2 (de) 1999-11-04
AU2715795A (en) 1995-09-21
HU9701084D0 (en) 1997-08-28
IE990988A1 (en) 2000-12-13
DE69232878D1 (de) 2003-01-30
DE69229114D1 (de) 1999-06-10
HU222111B1 (hu) 2003-04-28
WO1992015582A1 (en) 1992-09-17
SG46492A1 (en) 1998-02-20
CA2289219A1 (en) 1992-09-02
NO933069D0 (no) 1993-08-27
SG70625A1 (en) 2000-02-22
IE920605A1 (en) 1992-09-09
EP0582581A1 (de) 1994-02-16
JP2955019B2 (ja) 1999-10-04
PH31614A (en) 1999-01-12
UA32546C2 (uk) 2001-02-15
EP0872478A3 (de) 1998-11-04
DE69232878T2 (de) 2003-11-20
HU222250B1 (hu) 2003-05-28
HU222247B1 (hu) 2003-05-28
NO933069L (no) 1993-11-01
AU1566992A (en) 1992-10-06
HU9302457D0 (en) 1993-11-29
EP0872478B1 (de) 2002-12-18
AU673309B2 (en) 1996-10-31
IL101110A0 (en) 1992-11-15
HU9701083D0 (en) 1997-08-28

Similar Documents

Publication Publication Date Title
ATE229943T1 (de) Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen
DK0550113T3 (da) Triazolpyrimidinderivater med fungicid virkning
NO304946B1 (no) Xantinderivat samt dets anvendelse
PT920430E (pt) Derivados de purina e sua utilizacao como anticoagulantes
AU6947401A (en) Phenylpyridazine derivatives and drugs containing the same
ES2100299T3 (es) Compuestos silicicos fungicidas, su preparacion y su utilizacion en agroquimica y en medicina.
IL88303A (en) Derivatives of 6-fluoro-7-û4-( (5-methyl-2-oxo-1,3- dioxolen-4-yl)methyl) piperazin-1-ylù-4 (1h)-oxo-1,3-thiazeto(3,2-a) quinoline-3-carboxylic acid
DK0579968T3 (da) 4-Iminoquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse
ATE203537T1 (de) Pyrazol(1,5-a)pyrimidin derivate
ATE165815T1 (de) N-phenyl-2-cyano-3-hydroxypropenamide, ihre tautomeren, ihre salze, verfahren zu ihrer herstellung, ihre anwendung als medikamente und zusammensetzungen, die sie enthalten
ATE139767T1 (de) Verfahren zur herstellung 5-pyrazolomerkaptan- derivate und dessen zwischenprodukte
DE69218718D1 (de) Pharmazeutische Zusammensetzungen die Triazole Derivate enthalten zur rektalen Verabbrechung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0872478

Country of ref document: EP

REN Ceased due to non-payment of the annual fee